Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05659264 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure
A Phase 1 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT05659264 is a Phase 1 study that has completed, run by ModernaTX. The registered enrollment target is 48 participants.
The verdict
NCT05659264, a Phase 1 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses at escalating dose levels of mRNA-0184.
Interventions
- DRUG Placebo
- DRUG mRNA-0184
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2022-12-05 |
| Est. Completion | 2024-12-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05659264
The ClinicalTrials.gov registry entry for NCT05659264 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05659264 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05659264 about?
NCT05659264 is a clinical study titled "A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure". The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses at escalating dose levels of mRNA-0184.
What is the current status of trial NCT05659264?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2022-12-05. Estimated completion is 2024-12-17.
What interventions are being tested in trial NCT05659264?
The interventions under investigation include: Placebo (DRUG), mRNA-0184 (DRUG).
Who is sponsoring clinical trial NCT05659264?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.